Acurex Biosciences

Acurex’s platform and founding intellectual property are based on a Stanford University breakthrough discovery enabling the identification of druggable targets that induce biomarker changes in Parkinson's disease. Acurex’s platform has generated two oral small-molecule therapeutic programs that cross the blood-brain barrier and protect neurons derived from Parkinson’s disease patients. Acurex’s lead program has begun IND-enabling studies, and the second program to a distinct target is in lead development. Acurex is supported by funding from Stanford University, the University of California, the Michael J. Fox Foundation for Parkinson’s Research, Parkinson’s UK, The Silverstein Foundation for Parkinson’s with GBA, and the National Institute on Aging.